A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in patients with newly diagnosed malignant glioma. (BioWorld Today)
A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in patients with newly diagnosed malignant glioma. (BioWorld Today)
GAITHERSBURG, Md. A government panel on Tuesday flatly rejected ViroPharma Inc.’s application for Picovir, an investigational drug that reduces the duration of a cold by one day. (BioWorld Today)
GAITHERSBURG, Md. A government panel on Tuesday flatly rejected ViroPharma Inc.’s application for Picovir, an investigational drug that reduces the duration of a cold by one day. (BioWorld Today)
WASHINGTON In recent days, ViroPharma Inc. has been the subject of speculation surrounding the outcome of today’s government panel hearing on whether to recommend Picovir as a treatment for the common cold. (BioWorld Today)
WASHINGTON In recent days, ViroPharma Inc. has been the subject of speculation surrounding the outcome of today’s government panel hearing on whether to recommend Picovir as a treatment for the common cold. (BioWorld Today)
WASHINGTON - The National Institutes of Health expects to spend portions of its proposed $1.7 billion bioterrorism budget testing vaccines for threats such as anthrax, smallpox and botulism. (BioWorld Today)
WASHINGTON - The National Institutes of Health expects to spend portions of its proposed $1.7 billion bioterrorism budget testing vaccines for threats such as anthrax, smallpox and botulism. (BioWorld Today)
